vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $27.5M, roughly 6.6× Sanara MedTech Inc.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -5.9%, a 5.1% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
AVNS vs SMTI — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $27.5M |
| Net Profit | $-1.3M | $-1.6M |
| Gross Margin | 47.5% | 93.2% |
| Operating Margin | 1.4% | 23.5% |
| Net Margin | -0.7% | -5.9% |
| Revenue YoY | 0.7% | 4.6% |
| Net Profit YoY | 99.7% | 5.3% |
| EPS (diluted) | $-0.02 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $27.5M | ||
| Q3 25 | $177.8M | $26.3M | ||
| Q2 25 | $175.0M | $25.8M | ||
| Q1 25 | $167.5M | $23.4M | ||
| Q4 24 | $179.6M | $26.3M | ||
| Q3 24 | $170.4M | $21.7M | ||
| Q2 24 | $171.7M | $20.2M | ||
| Q1 24 | $166.1M | $18.5M |
| Q4 25 | $-1.3M | $-1.6M | ||
| Q3 25 | $-1.4M | $-30.4M | ||
| Q2 25 | $-76.8M | $-2.0M | ||
| Q1 25 | $6.6M | $-3.5M | ||
| Q4 24 | $-397.3M | $-1.7M | ||
| Q3 24 | $4.3M | $-2.9M | ||
| Q2 24 | $1.8M | $-3.5M | ||
| Q1 24 | $-900.0K | $-1.8M |
| Q4 25 | 47.5% | 93.2% | ||
| Q3 25 | 48.4% | 92.9% | ||
| Q2 25 | 52.6% | 92.5% | ||
| Q1 25 | 53.6% | 92.2% | ||
| Q4 24 | 54.6% | 91.4% | ||
| Q3 24 | 54.5% | 90.8% | ||
| Q2 24 | 55.7% | 90.0% | ||
| Q1 24 | 57.1% | 89.8% |
| Q4 25 | 1.4% | 23.5% | ||
| Q3 25 | 0.1% | 11.2% | ||
| Q2 25 | -42.6% | -0.1% | ||
| Q1 25 | 6.1% | -8.9% | ||
| Q4 24 | -233.0% | 18.6% | ||
| Q3 24 | 7.0% | 3.6% | ||
| Q2 24 | 3.7% | -14.3% | ||
| Q1 24 | 2.4% | -8.3% |
| Q4 25 | -0.7% | -5.9% | ||
| Q3 25 | -0.8% | -115.5% | ||
| Q2 25 | -43.9% | -7.8% | ||
| Q1 25 | 3.9% | -15.1% | ||
| Q4 24 | -221.2% | -6.5% | ||
| Q3 24 | 2.5% | -13.2% | ||
| Q2 24 | 1.0% | -17.4% | ||
| Q1 24 | -0.5% | -9.5% |
| Q4 25 | $-0.02 | $-0.32 | ||
| Q3 25 | $-0.03 | $-3.40 | ||
| Q2 25 | $-1.66 | $-0.23 | ||
| Q1 25 | $0.14 | $-0.41 | ||
| Q4 24 | $-8.64 | $-0.18 | ||
| Q3 24 | $0.09 | $-0.34 | ||
| Q2 24 | $0.04 | $-0.41 | ||
| Q1 24 | $-0.02 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $16.6M |
| Total DebtLower is stronger | $90.3M | $46.0M |
| Stockholders' EquityBook value | $778.2M | $5.9M |
| Total Assets | $1.1B | $72.9M |
| Debt / EquityLower = less leverage | 0.12× | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $16.6M | ||
| Q3 25 | $70.5M | $14.9M | ||
| Q2 25 | $90.3M | $17.0M | ||
| Q1 25 | $97.0M | $20.7M | ||
| Q4 24 | $107.7M | $15.9M | ||
| Q3 24 | $89.0M | $16.3M | ||
| Q2 24 | $92.2M | $6.2M | ||
| Q1 24 | $75.8M | $2.8M |
| Q4 25 | $90.3M | $46.0M | ||
| Q3 25 | $93.4M | $45.1M | ||
| Q2 25 | $95.7M | $44.2M | ||
| Q1 25 | $98.0M | $43.4M | ||
| Q4 24 | $125.3M | $30.7M | ||
| Q3 24 | $152.6M | $30.1M | ||
| Q2 24 | $164.9M | $14.4M | ||
| Q1 24 | $167.2M | $9.7M |
| Q4 25 | $778.2M | $5.9M | ||
| Q3 25 | $778.0M | $6.1M | ||
| Q2 25 | $776.3M | $35.4M | ||
| Q1 25 | $839.4M | $36.7M | ||
| Q4 24 | $828.5M | $39.4M | ||
| Q3 24 | $1.2B | $39.8M | ||
| Q2 24 | $1.2B | $41.7M | ||
| Q1 24 | $1.2B | $43.3M |
| Q4 25 | $1.1B | $72.9M | ||
| Q3 25 | $1.1B | $71.1M | ||
| Q2 25 | $1.0B | $98.8M | ||
| Q1 25 | $1.1B | $96.4M | ||
| Q4 24 | $1.2B | $88.1M | ||
| Q3 24 | $1.7B | $88.5M | ||
| Q2 24 | $1.7B | $73.4M | ||
| Q1 24 | $1.7B | $70.9M |
| Q4 25 | 0.12× | 7.74× | ||
| Q3 25 | 0.12× | 7.33× | ||
| Q2 25 | 0.12× | 1.25× | ||
| Q1 25 | 0.12× | 1.18× | ||
| Q4 24 | 0.15× | 0.78× | ||
| Q3 24 | 0.12× | 0.76× | ||
| Q2 24 | 0.13× | 0.34× | ||
| Q1 24 | 0.14× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $3.9M |
| Free Cash FlowOCF − Capex | $21.3M | $3.9M |
| FCF MarginFCF / Revenue | 11.8% | 14.0% |
| Capex IntensityCapex / Revenue | 3.8% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $3.9M | ||
| Q3 25 | $14.0M | $2.2M | ||
| Q2 25 | $6.8M | $2.7M | ||
| Q1 25 | $25.7M | $-2.0M | ||
| Q4 24 | $57.9M | $932.0K | ||
| Q3 24 | $23.0M | $2.1M | ||
| Q2 24 | $27.8M | $-1.4M | ||
| Q1 24 | $-8.0M | $-1.6M |
| Q4 25 | $21.3M | $3.9M | ||
| Q3 25 | $7.0M | $1.1M | ||
| Q2 25 | $-4.2M | $902.7K | ||
| Q1 25 | $19.0M | $-3.7M | ||
| Q4 24 | $53.1M | $859.9K | ||
| Q3 24 | $20.0M | $2.0M | ||
| Q2 24 | $21.9M | $-1.5M | ||
| Q1 24 | $-12.1M | $-1.7M |
| Q4 25 | 11.8% | 14.0% | ||
| Q3 25 | 3.9% | 4.2% | ||
| Q2 25 | -2.4% | 3.5% | ||
| Q1 25 | 11.3% | -15.9% | ||
| Q4 24 | 29.6% | 3.3% | ||
| Q3 24 | 11.7% | 9.4% | ||
| Q2 24 | 12.8% | -7.3% | ||
| Q1 24 | -7.3% | -9.0% |
| Q4 25 | 3.8% | 0.3% | ||
| Q3 25 | 3.9% | 4.0% | ||
| Q2 25 | 6.3% | 6.8% | ||
| Q1 25 | 4.0% | 7.4% | ||
| Q4 24 | 2.7% | 0.3% | ||
| Q3 24 | 1.8% | 0.0% | ||
| Q2 24 | 3.4% | 0.3% | ||
| Q1 24 | 2.5% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
